Related papers: CAR T cells for T-cell leukemias: Insights from ma…
Immunotherapies use components of the patient immune system to selectively target cancer cells. The use of CAR T cells to treat B-cell malignancies --leukaemias and lymphomas-- is one of the most successful examples, with many patients…
CAR-T cell therapies have demonstrated significant success in treating B-cell leukemia in children and young adults. However, their effectiveness in treating B-cell lymphomas has been limited. Unlike leukemia, lymphoma often manifests as…
Chimeric Antigen Receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. This paper makes an analytical and numerical study of a mathematical model describing the competition of CAR-T,…
Cellular immunotherapies are one of the mainstream cancer treatments unveiling the power of the patient's immune system to fight tumors. CAR T-cell therapy, based on genetically engineered T cells, has demonstrated significant potential in…
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising treatment for hematological malignancies, offering a targeted approach to cancer treatment. Understanding the complexities of CAR-T cell therapy within solid tumors…
Chimeric antigen receptor (CAR) T cell therapy is revolutionizing the treatment of blood cancers. Mathematical models that can predict the effectiveness of immunotherapies such as CAR T are of increasing interest due to their ability to…
Chimeric Antigen Receptor (CAR) T-cell therapy is an immunotherapy that has recently become highly instrumental in the fight against life-threatening diseases. A variety of modeling and computational simulation efforts have addressed…
Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated. For glioma brain tumors, various CAR T-cell…
We study the dynamics and interactions between combined chemotherapy and chimeric antigen receptor (CAR-T) cells therapy and malignant gliomas (MG). MG is one of the most common primary brain tumor, with high resistance to therapy and…
As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors…
Chimeric Antigen Receptor (CAR) T cell therapy has transformed immunotherapy for resistant cancers, yet it faces major limitations such as lack of persistence, toxicity, exhaustion, and antigen-negative relapse. Enhancing CAR T cells with…
Immunotherapy is currently regarded as the most promising treatment to fight against cancer. This is particularly true in the treatment of chronic lymphocytic leukemia, an indolent neoplastic disease of B-lymphocytes which eventually causes…
Immunotherapies have been proven to have significant therapeutic efficacy in the treatment of cancer. The last decade has seen adoptive cell therapies, such as chimeric antigen receptor T-cell (CART-cell) therapy, gain FDA approval against…
The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment,…
Following antigen stimulation, the net outcomes of a T cell response are shaped by integrated signals from both positive co-stimulatory and negative regulatory molecules. Recently, the blockade of negative regulatory molecules (i.e. immune…
While the use of combination therapy is increasing in prevalence for cancer treatment, it is often difficult to predict the exact interactions between different treatment forms, and their synergistic/antagonistic effects on patient health…
Mathematical oncology is a rapidly evolving interdisciplinary field that uses mathematical models to enhance our understanding of cancer dynamics, including tumor growth, metastasis, and treatment response. Tumor-immune interactions play a…
Chimeric antigen receptor T-cell (CAR-T) therapy is considered a promising cancer treatment. The dynamic response to this therapy can be broadly divided into a short-term phase, ranging from weeks to months, and a long-term phase, ranging…
Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved,…
There is evidence of synergy between radiotherapy and immunotherapy. Radiotherapy can increase liberation of tumor antigens, causing activation of antitumor T-cells. This effect can be boosted with immunotherapy. Radioimmunotherapy has…